Andreas Hochhaus
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 664
- Chronic Myeloid Leukemia Treatments 605
- Acute Myeloid Leukemia Research 92
- Genetics 491
- Chronic Lymphocytic Leukemia Research 424
- Myeloproliferative Neoplasms: Diagnosis and Treatment 80
- Co-authors
- Timothy P. Hughes (139 shared papers)Hagop M. Kantarjian (136 shared papers)Giuseppe Saglio (107 shared papers)Rüdiger Hehlmann (117 shared papers)Michele Baccarani (75 shared papers)Jörge E. Cortes (155 shared papers)Richard A. Larson (60 shared papers)François Guilhot (41 shared papers)
- Journals
- Blood (248 papers)Journal of Clinical Oncology (104 papers)Leukemia (93 papers)Journal of Cancer Research and Clinical Oncology (53 papers)Annals of Hematology (23 papers)
- Partner nations
- GermanyUnited StatesItaly
In The Last Decade
Andreas Hochhaus
808 papers receiving 39.6k citations
Andreas Hochhaus's Hit Papers
Peers
Comparison fields: 5 of 172
- Hematology 29.7k
- Genetics 19.6k
- Rheumatology 12.8k
- Oncology 6.2k
- Pathology and Forensic Medicine 2.5k
Countries citing papers authored by Andreas Hochhaus
This map shows the geographic impact of Andreas Hochhaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Hochhaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Hochhaus more than expected).
Fields of papers citing papers by Andreas Hochhaus
This network shows the impact of papers produced by Andreas Hochhaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Hochhaus. The network helps show where Andreas Hochhaus may publish in the future.
Co-authors
The 25 scholars most cited alongside Andreas Hochhaus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 846 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia Hit paper breakdown → | 2002 | 1523 |
| 2 | Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer Hit paper breakdown → | 2013 | 1296 |
| 3 | Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia Hit paper breakdown → | 2010 | 1193 |
| 4 | Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Hit paper breakdown → | 2010 | 1108 |
| 5 | Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL Hit paper breakdown → | 2006 | 974 |
| 6 | Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia Hit paper breakdown → | 2003 | 907 |
| 7 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 892 |
| 8 | Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Hit paper breakdown → | 2017 | 814 |
| 9 | Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Hit paper breakdown → | 2010 | 812 |
| 10 | Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Hit paper breakdown → | 2002 | 679 |
| 11 | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial Hit paper breakdown → | 2016 | 631 |
| 12 | Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Hit paper breakdown → | 2009 | 628 |
| 13 | Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial Hit paper breakdown → | 2016 | 568 |
| 14 | Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Hit paper breakdown → | 2007 | 542 |
| 15 | 2007 | 455 | |
| 16 | 2006 | 447 | |
| 17 | International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Hit paper breakdown → | 2009 | 446 |
| 18 | Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Hit paper breakdown → | 2011 | 444 |
| 19 | 2011 | 379 | |
| 20 | 2003 | 378 |
About Andreas Hochhaus
Andreas Hochhaus is a scholar working on Hematology, Genetics, Rheumatology, Public Health, Environmental and Occupational Health and Oncology, having authored 846 papers that have together received 40.6k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (605 papers), Chronic Lymphocytic Leukemia Research (424 papers), Eosinophilic Disorders and Syndromes (242 papers), Acute Lymphoblastic Leukemia research (95 papers), Acute Myeloid Leukemia Research (92 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (80 papers), Lymphoma Diagnosis and Treatment (49 papers) and Click Chemistry and Applications (27 papers). The work is most often cited by research in Hematology (29.7k citations), Genetics (19.6k citations), Rheumatology (12.8k citations), Oncology (6.2k citations) and Pathology and Forensic Medicine (2.5k citations). Andreas Hochhaus has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Timothy P. Hughes, Hagop M. Kantarjian, Giuseppe Saglio, Rüdiger Hehlmann, Michele Baccarani, Jörge E. Cortes, Richard A. Larson, François Guilhot, Jerald P. Radich and Brian Druker. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Journal of Cancer Research and Clinical Oncology and Annals of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.